Abstract
AbstractNarcolepsy (affects 1/2000 of the general population) is characterized by excessive daytime sleepiness, cataplexy, and other dissociated manifestations of rapid eye movement sleep (hypnagogic hallucinations and sleep paralysis). The disease is currently treated with amphetamine‐like compounds and modafinil for EDS and anticataplectics (antidepressants) for cataplexy. The major pathophysiology of human narcolepsy has recently been revealed by the extension of discoveries of narcolepsy genes in animal models: about 90% of human narcolepsy‐cataplexy has been found to be hypocretin/orexin ligand deficient. This directly led to the development of new diagnostic tests (i.e., CSF hypocretin measures). Hypocretin replacement is also likely to be a new therapeutic option for hypocretin deficient narcolepsy, but this is still not available in humans. Clinical and pharmacological aspects of narcolepsy as well as future directions are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
